re:up by10.9 percent today, page-7

Just like to add that i see that CSL are making a 79% premium bid over another small bio in the market.

Are we seeing the first sign of consolidation within the Australian biotech sector? This will lead to some very successful companies IMHO where the cash flow element to commercialising the great idea can be eliminated.

The question then remains, just how much consolidation will happen and how much will stay here.

My point here is that surely ACL becomes an option for someone else??? They certainly have indicated a listing in the US....